By Nono Hu, Director of Marketing, LSN
RESI JPM 2019 was the biggest Redefining Early Stage Investments event yet. In a highly competitive RESI Innovation Challenge we saw novel technologies represented from the therapeutics, medtech, diagnostics, and digital health verticals – we know it was tough for RESI attendees to choose how to allocate their 5 RESI “investment” tokens! We wish all our finalists the best in bringing their products forward toward commercialization, but there could only be 3 top prize winners.
First Place: Novotalk
Novotalk provides an end-to-end digital therapy for people with speech disorders. It’s an online, on-demand (asynchronous), self-directed speech tele-therapy solution, which allows those with speech impairments to learn, practice, gain, and maintain comprehensible speech remotely, independently, and discretely. The user goes through therapy with a virtual clinician, together with algorithms that detect pre-defined speech patterns and provide feedback in real-time. The “real” clinician is a data-empowered supervisor to the process. We make therapy accessible, by removing the 2 main barriers to therapy; clinician availability and affordability. Novotalk’s first solution addresses stuttering, a condition which affects 370m people globally.
Jonathan Oron,VP R&D, Novotalk | Lilach Shvimer-Rothschild, Co-founder & COO, Novotalk | Dennis Ford, Founder & CEO, Life Science Nation | Zohar Beeri, CEO, Novotalk | Karen Deyo, Investor Research Analyst, Life Science Nation
Second Place: Heroic-Faith Medical Science
Established in June 2018, Heroic-Faith Medical Science Corp., LTD. is focused on the development of medical devices for the critical care medicine. The total annual spending on ICU care in North America in 2018 reaches $108 billion USD, being second only to cancer care which totals $158 billion USD, making it a key market that is marked by costly spending, as well as one that is open to new ideas. We hope to combine Taiwan’s advanced medical expertise with its cutting-edge electronics capabilities to develop break-through products, so that we can realize the ideal of our CEO, “Saving lives through innovation”, in the global market.
Fushun Hsu, CEO, Heroic-Faith Medical Science | Yuan-Ren Cheng, COO, Heroic-Faith Medical Science | Dennis Ford, Founder & CEO, Life Science Nation | Lucy Parkinson, VP of Investor Research, Life Science Nation
Third Place: MedTrace A/S
MedTrace is a development-stage company innovating PET diagnostic imaging with an end-to-end solution for a best-in-class blood flow tracer geared for better outcomes, attractive economics and high-patient throughput.
• PET scans are the most sensitive and precise diagnostic tools available in medical imaging.
• There is a significant unmet need in cardiology for improved diagnostic images to guide invasive and non-invasive treatment.
• One of the fundamental challenges in PET cardiology diagnostics is the global scarcity of tracers.
• MedTrace has developed a solution that enables the practical incorporation of the gold-standard radiotracer, 15O-water, for PET cardiology imaging.
• MedTrace’s beachhead will be in the inefficiently-served Myocardial Ischemia market.
Rune Wiik Kristensen, COO, MedTrace | Martin Stenfeldt, CEO, MedTrace | Dennis Ford, Founder & CEO, Life Science Nation | Lucy Parkinson, VP of Investor Research, Life Science Nation
Leave a Reply